Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer

[1]  Kunihiko Kobayashi,et al.  Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1 , 2022, BMC cancer.

[2]  H. Wada,et al.  Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients , 2022, Scientific Reports.

[3]  Yan Xu,et al.  Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer , 2022, Frontiers in Immunology.

[4]  A. Madabhushi,et al.  Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer , 2022, Journal for ImmunoTherapy of Cancer.

[5]  J. Utikal,et al.  Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[6]  T. Kodama,et al.  Absolute Increase in the Number and Proportion of Peripheral Eosinophils Associated With Immune Checkpoint Inhibitor Treatment in Non-small Cell Lung Cancer Patients. , 2021, Cancer Diagnosis & Prognosis.

[7]  E. Felip,et al.  Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  A. Tafreshi,et al.  Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Ando,et al.  A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors , 2020, Cancer Immunology, Immunotherapy.

[10]  S. Amigorena,et al.  A dendritic cell multitasks to tackle cancer , 2020, Nature.

[11]  Wei-min Li,et al.  Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis , 2020, BMJ Open.

[12]  K. Tobe,et al.  Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor , 2019, AntiCancer Research.

[13]  G. Kochan,et al.  Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy , 2019, EMBO molecular medicine.

[14]  N. Chaput,et al.  Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. , 2019, European journal of cancer.

[15]  H. Dai,et al.  Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer , 2018, Front. Immunol..

[16]  Shuofeng Hu,et al.  Dynamic testing of stimulative and suppressive biomarkers on peripheral blood cells at early stages of immunotherapy predicts response in advanced cancer patients. , 2018, Discovery medicine.

[17]  K. Flaherty,et al.  Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.

[18]  D. Schadendorf,et al.  Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. , 2017, European journal of cancer.

[19]  Sean S. Park,et al.  T cell Bim levels reflect responses to anti-PD-1 cancer therapy. , 2016, JCI insight.

[20]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[21]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[22]  Kayoko Waki,et al.  PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer , 2014, Cancer science.

[23]  I. Lowy,et al.  T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment , 2013, Cancer Immunology, Immunotherapy.

[24]  Michael J. Zilliox,et al.  Phenotype, Function, and Gene Expression Profiles of Programmed Death-1hi CD8 T Cells in Healthy Human Adults , 2011, The Journal of Immunology.

[25]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[26]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Schmidt.  Meta-Analysis , 2008 .